Inclusion Criteria:  Lung allograft recipients Age ≥16 years at time of enrollment ≥1 month and <36 months post-lung transplant Anticipated to be available for duration of the study Can be reached by telephone, email, or text message  Exclusion Criteria:  Recipient of multi-organ, extra-pulmonary, and/or hematopoietic stem cell transplant Recipient of a re-do lung transplant History of severe hypersensitivity to previous influenza vaccination or anaphylaxis to eggs/egg protein History of Guillain-Barre syndrome HIV positive patients History of known severe latex hypersensitivity History of receiving the current season's influenza vaccine post-transplant prior to enrollment in the study Pregnant female Proven influenza disease after September 1st and before first study vaccine (patient can still receive the second influenza vaccination despite proven influenza disease once enrolled) CMVIG/IVIG/SCIG receipt within 28 days of each vaccine Receipt of rituximab or other B-cell depleting antibody (including proteasome inhibitors) therapy within 3-months of 1st study vaccine (Day 0). Receipt of augmented T-cell depleting therapy within 3-months of 1st study vaccine (Day 0) Investigator concern about study participation